¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"linear IgA dermatosis of adulthood"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® linear accelerator ÇÑ±Û ¼±»ó°¡¼Ó±â
¼³¸í   
  Ä¡·á¹æ»ç¼±°ú¿¡¼­ ÀÌ¿ëÇϴ ±â°è·Î¼­ ÀüÀÚ¸¦ »ý¼ºÇØ ³½´Ù. ÀüÀڴ ´Ü¼øÈ÷ X-¼±°ú´Â ´Ù¸¥ °ÍÀ¸·Î ÀüÀÚ°¡ ±Ý¼Ó¿¡ ºÎµúÇô ³ª¿À´Â °ÍÀÌ X-¼±ÀÌ´Ù. ÀüÀڴ Áø´Ü¸ñÀûº¸´Ù´Â Ä¡·á¸ñÀûÀ¸·Î ÁַΠÇǺÎÀÇ ¾Ç¼ºÁ¾¾ç(¾Ï)¿¡ »ç¿ëµÈ´Ù.
¿µ¹® adulthood ÇÑ±Û ¼ºÀαâ
¼³¸í   
  Å¾ƿ¡¼­ ¼Ò¾Æ±â¿Í Ã»³â±â¸¦ °ÅÃÄ ¼ºÀåÀÌ ¿Ï·áµÈ ½ÃÁ¡¿¡¼­ ³ë³â±â±îÁöÀÇ ±â°£ º¸Åë 20~60¼¼±îÁö¸¦ ¸»ÇÑ´Ù. ÇÑâ ÀÏÇÒ ½Ã±â·Î¼­ »çȸ»ýȰ°ú °¡Á¤»ýȰ¿¡ À־ Ãæ½ÇÇϰԠ³ë·ÂÇϴ ½Ã±âÀ̱⵵ ÇÏ´Ù. ±×·¯³ª Ã¼·ÂÀº 25¼¼¸¦ Á¤Á¡À¸·Î ¿¬·É°ú ÇÔ²² Çϰ­¼±À» °È´Â ½Ã±â¿¡ ÇØ´çÇϸç, Æ¯È÷ 40¼¼ Áß¹ÝÀ» °íºñ·Î Ã¼·Â°ú ¿îµ¿´É·ÂÀÌ ¼è¾àÇØÁö±â ¶§¹®¿¡ Àû´çÇÑ ¿îµ¿ÀÌ ÇÊ¿äÇϰԠµÇ´Â ½Ã±âÀ̱⵵ ÇÏ´Ù. ¶Ç ¾Ï, ´ç´¢º´, ½ÉÀ庴, °íÇ÷¾Ð, µ¿¸Æ°æÈ­Áõ µî ¼ÒÀ§ ¼ºÀκ´ÀÌ ³ªÅ¸³ª´Â ¶§À̸ç, Æ¯È÷ ½É±Ù°æ»ö, ³úÁßdz µî°ú °°Àº µ¿¸Æ°æÈ­°¡ ¿øÀÎÀÌ µÇ´Â ÁúȯÀÌ 40´ë¿¡ Áõ°¡Çϴ °æÇâÀÌ Àֱ⠶§¹®¿¡ Á¤±âÀûÀ¸·Î °ËÁøÀ» ¹Þ¾Æ º´ÀÇ ¿¹¹æ°ú Á¶±â¹ß°ß¿¡ ½Å°æÀ» ½á¾ß Çϴ ½Ã±âÀÌ´Ù.
¿µ¹® dermatosis ÇÑ±Û ÇǺκ´
¼³¸í   
  ÇǺο¡ »ý±â´Â ¸ðµç º´ÀÇ ÃÑĪ. ÇǺδ ½ÅüÀǠǥ¸éÀ» µ¤°í ÀÖÀ¸¹Ç·Î ¿Ü°è·ÎºÎÅÍ ÀÚ±ØÀ̳ª ¿©·¯ º´¿øÃ¼¿¡ Á÷Á¢ Á¢Ã˵ɠ±âȸ°¡ ¸¹°í, Ã¼³»·ÎºÎÅÍ ¿µÇâÀ» °­ÇϰԠ¹Þ´Â´Ù. ´õ¿íÀÌ ÇǺÎÀÇ ±Ù¼ÒÇÑ º¯È­µµ ´«À¸·Î º¸°í ¼ÕÀ¸·Î ¸¸Áú ¼ö ÀÖÀ¸¸ç, º´º¯ºÎÀÇ ÀϺθ¦ Ã¤ÃëÇÏ¿© º´¸®Á¶Á÷ÇÐÀûÀ¸·Î °Ë»çÇϰųª, ¹Ì»ý¹°ÀÇ °Ë»ö µîÀÇ °Ë»ç¸¦ Çϱ⠽±°í, °³°³ÀÇ Áúº´ÀÇ Áø´ÜÀ» ¸íÈ®ÇϰԠÇϴ °ÍÀÌ ¿ëÀÌÇϹǷÎ, ±× Á¾·ù´Â ´Ù¸¥ Àå±âÀÇ ±×°Í¿¡ ºñÇÏ¿© »ó´çÇÑ ¼ö¿¡ À̸£¸ç, º´¸íµµ º¹Àâ ´Ù¾çÇÏ´Ù. Å©°Ô ³ª´©¸é ´ÙÀ½°ú °°´Ù. º¯È­°¡ ÇǺο¡ ÇÑÁ¤µÈ °Í¿¡´Â ¹ÝÁ¡-Á¡ µîÀÌ ÀÖ°í, Àü½Å¿¡ ¹ÌÄ¡´Â °Í¿¡´Â ¾Æ±³Áúº´, ºñŸ¹Î°áÇ̼º ÇǺκ´, ³»ºÐºñÀå¾Ö¼º ÇǺκ´ µîÀÌ Æ÷ÇԵȴÙ. ´Ù¸¸ ÇǺθ¦ Á¦¿ÜÇÑ ºÎºÐÀ» ÇǺο¡ ´ëÇÏ¿© Àü½ÅÀ¸·Î °£ÁÖÇϴ °æ¿ì, º¯È­°¡ ÇǺο¡¸¸ ÇÑÁ¤µÇ´Â °ÍÀº Àû°í, ´ëºÎºÎºÐÀÇ ÇǺκ´Àº Ç÷¾×ÀÇ º¯È­³ª °£±â´ÉÀå¾Ö µîÀÇ Àü½ÅÇö»óÀ» ¼ö¹ÝÇÑ´Ù. ¼¼±Õ-¹ÙÀÌ·¯½º µîÀÇ º´¿øÃ¼°¡ ¿øÀÎÀΠÁúº´¿¡´Â ¼öµÎ-³ó°¡Áø-¸Åµ¶ µîÀÌ ÀÖ°í, °¢°¢ Àü¿°ÇÏÁö¸¸, ½ÀÁø-¹ÝÁ¡-Á¾¾ç ¶Ç´Â ¾Æ±³Áúº´ µîÀº Àü¿°ÇÏÁö ¾Ê´Â´Ù. ÇǺκ´ÀÇ ³»ÀÎÀ¸·Î´Â À§ÀåÀå¾Ö-°£º´-ÄáÆÏº´-¹°Áú´ë»çÀå¾Ö-Ç÷¾×Áúȯ-³»ÀåÁ¾¾ç-³»ºÐºñÀå¾Ö µîÀ» µé ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adulthood
    ¼ºÀαâ
  • IgA nephropathy
    IgAÄáÆÏº´(Áõ), IgA½ÅÀ庴(Áõ)
  • acquired perforating dermatosis
    ÈÄõõ°øÇǺκ´
  • benign papular acantholytic dermatosis
    ¾ç¼º±¸Áø°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • bullous dermatosis
    ¹°ÁýÇǺκ´
  • dermatosis
    ÇǺκ´
  • lichenoid dermatosis
    ż±¸ð¾çÇǺκ´
  • occupational dermatosis
    Á÷¾÷ÇǺκ´
  • progressive pigmentary dermatosis
    ÁøÇà»ö¼ÒÇǺκ´
  • parasitic dermatosis
    ±â»ýÃæÇǺκ´
  • persistent acantholytic dermatosis
    Áö¼Ó°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • reticulate pigmented dermatosis
    ±×¹°»ö¼ÒÇǺκ´, ¸Á»ó»ö¼ÒÇǺκ´
  • general linear model
    ÀϹݼ±Çü¸ðµ¨
  • linear
    ÁÙ(¸ð¾ç)-, ¼±Çü-, ¼±»ó-
  • linear acceleration
    ¼±Çü°¡¼Óµµ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adulthood
    ¼ºÀαâ
  • dermatosis
    ÇǺκ´
  • IgA nephropathy
    ¸é¿ª±Û·Îºí¸°¿¡ÀÌÄáÆÏº´Áõ, ¸é¿ª±Û·Îºí¸°¿¡À̽ÅÀ庴Áõ
  • linear acceleration
    ¼±Çü°¡¼Ó
  • linear fracture
    ¼±°ñÀý
  • linear regression
    ¼±Çüȸ±Í
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • linear lichenoid dermatosis
    ¼±»óż±¸ð¾çÇǺκ´
  • adulthood
    ¼ºÀαâ
  • acquired perforating dermatosis
    ÈÄõõ°øÇǺκ´
  • benign papular acantholytic dermatosis
    ¾ç¼º±¸Áø°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • bullous dermatosis
    ¹°ÁýÇǺκ´
  • dermatosis
    ÇǺκ´
  • lichenoid dermatosis
    ż±¸ð¾çÇǺκ´
  • occupational dermatosis
    Á÷¾÷ÇǺκ´
  • parasitic dermatosis
    ±â»ýÃæÇǺκ´
  • peridigital dermatosis
    ¼Õ°¡¶ôÁÖÀ§ÇǺκ´
  • persistent acantholytic dermatosis
    Áö¼Ó°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
  • progressive pigmentary dermatosis
    ÁøÇà»ö¼ÒÇǺκ´
  • pustular dermatosis
    ÀÜ°í¸§ÁýÇǺκ´
  • reticulate pigmented dermatosis
    ±×¹°»ö¼ÒÇǺκ´
  • transient acantholytic dermatosis
    Àϰú¼º°¡½Ã¼¼Æ÷ÇØ¸®ÇǺκ´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adulthood
    ¼ºÀαâ
  • IgA, secretory
    ºÐºñÇü IgA
  • anti-IgA
    Ç× IgA Ç×ü
  • iga deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ
  • iga nephroathy
    ¸é¿ª±Û·ÎºÒ¸° A ½Åº´Áõ
  • immunoglobulin a(iga)
    ¸é¿ª±Û·ÎºÒ¸° A(Øó湡­)
  • Linear acceleration
    ¼±»ó°¡¼Ó(àÊ߾ʥáÜ)
  • arrays, linear sequenced
    ¼±Çü ¼øÂ÷ ¹è¿­ (àÊû¡ â÷ó­ ÛÉæê)
  • high linear energy transfer radiation
    °í¼±Çü¿¡³ÊÁöÀüÀ̹æ»ç¼±
  • phased linear array type
    À§»óÂ÷ ¼±Çü ¹è¿­½Ä
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • radiation,linear energy transfer (let)
    ¼±»ó¿¡³ÊÁöÀüȯ(àÊß¾¡­ï®üµ)
  • Dermatosis
    ÇǺκ´
  • Gougerot-Blum pigmented purpuric lichenoid dermatosis
    ±¸Á¦·Î ºí·ë »ö¼Ò¼º Àڹݼº ż±¾ç ÇǺκ´
  • Grovers disease => transient acantholytic dermatosis
    Àϰú¼º ±Ø¼¼Æ÷ÇØ¸® ÇǺÎÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bullous dermatosis,linear iga
    ¼±»ó IgA (àÊß¾¡­)
  • linear IgA dermatosis
    ¼±»ó ¸é¿ª±Û·ÎºÒ¸°A ÇǺκ´(Áõ)
  • intra-epidermal neutrophilic IgA dermatosis
    Ç¥Çdz»È£Áß±¸¼º ¸é¿ª±Û·ÎºÒ¸°A ÇǺκ´
  • linear IgA bullous dematosis
    ¼±»ó ¸é¿ª±Û·ÎºÒ¸°A ¼öÆ÷¼ºÇǺκ´
  • linear IgA dermatitis
    ¼±»ó ¸é¿ª±Û·ÎºÒ¸°A ÇǺο°
  • adulthood
    ¼ºÀαâ
  • linear lichenoid dermatosis
    ¼±»ó ż±¾ç ÇǺκ´
  • anti-IgA
    Ç× IgA Ç×ü
  • iga deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ
  • iga nephroathy
    ¸é¿ª±Û·ÎºÒ¸° A ½Åº´Áõ
  • immunoglobulin a(iga)
    ¸é¿ª±Û·ÎºÒ¸° A(Øó湡­)
  • isolated iga deficiency
    ´Üµ¶¼º¸é¿ª±Û·ÎºÒ¸°A°áÇÌ(Ó¤Ô¼àõ Øóæ¹ ¡­ ÌÀù¹)
  • secretory IgA
    ºÐºñÇü IgA.
  • acquired perforating dermatosis
    ÈÄõ¼º õ°ø¼º ÇǺκ´
  • acquired reactive perforating dermatosis
    ÈÄõ¼º ¹ÝÀÀ¼º õ°ø¼º ÇǺκ´
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • parasitic dermatosis
    ÇǺαâ»ýÃæÁõ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • IgA
    (å²) immunoglobulin A
  • linear absorption coefficient
    ¼±Èí¼ö°è¼ö(àÊýåâ¥Ìõâ¦)
  • linear accelerator
    ¼±Çü°¡¼Ó±â(àÊû¡Ê¥áÜѦ)
  • linear chain
    ¼±Çü(àÊû¡)»ç½½
  • linear correlation
    ¼±Çü »ó°ü(àÊû¡ßÓμ)
  • linear density gradient
    ¼± ¹Ðµµ(à»ÚËÓø)±â¿ï±â
  • linear dichroism
    ¼±Çü ÀÌ»ö¼º(àÊû¡ì£ßäàõ)
  • linear electric field effect
    ¼±Çü Àü±âÀåÈ¿°ú(àÊû¡ï³Ñ¨íÞüùÍý)
  • linear energy transfer
    ¼±Çü(àÊû¡) ¿¡³ÊÁöÀüÀÌ(ï®ì¹)
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
  • linear inhibition
    ¼±ÇüÀúÇØ(àÊû¡îÁúª)
  • linear metabolic pathway
    ¼±Çü ´ë»ç°æ·Î(àÊû¡ÓÛÞóÌèÖØ)
  • linear polymer
    ¼±ÇüÁßÇÕü(àÊû¡ñìùêô÷)
  • linear polyphosphate
    ¼±ÇüÁßÀλê(àÊû¡ñììÝß«)
  • linear regression
    ¼±Çüȸ±Í(àÊû¡üÞÏý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • digital linear tape(DLT)
    µðÁöÅÐ Å×ÀÌÇÁ ÀúÀåÀåÄ¡
  • fine horizontal linear opacity
    ¹Ì¼¼ÇÑ ¼öÆò¸éÇü ¼±»ó ºÒÅõ¸íü
  • general linear model
    ÀϹÝÀû ¼±Çü¸ðµ¨, ÀÏ¹Ý ¼±»ó¸ðµ¨
  • linear
    ¼±»ó, ¼±Çü
  • linear accelerator
    ¼±Çü°¡¼Ó±â
  • linear array
    ¼±Çü ¹è¿­
  • linear correlation
    ¼±»ó»ó°ü
  • linear density
    ¼±»óÀ½¿µ
  • linear electronic scanner
    ¼±ÇüÀüÀڽĽºÄ³³Ê
  • linear fracture
    ¼±»ó°ñÀý
  • linear interpolation algorithm(LIA)
    ¼±»óº¸°£¿¬»ê
  • linear phased array
    ¼±ÇüÀ§»óÂ÷¹è¿­
  • linear scan
    ¼±Çü½ºÄµ
  • linear scan motion
    ¼±Çü½ºÄµ¿îµ¿
  • linear sequenced array
    ¼±Çü¿¬¼â¹è¿­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
GIDAANT Gender Identity Disorder of Adolescence or Adulthood, Non-transsexual Type
Ig Immuno-globulin
  IgA; Immuno-globulin A; (27)(30)60(100) - (170)(80)(250)380 mg/dL
IGA infantile genetic agranulocytosis
IgA immunoglobulin A
S-IgA secretory immunoglobulin A
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LABD Linear IgA bullous dermatosis
IgA-D IgA deficiency
IgA GN IgA glomerulonephritis
IgA-IC IgA immune complex
IgA NP IgA nephropathy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • linear IgA disease
    ¼±»ó ¸é¿ª ±Û·ÎºÒ¸° A Áúȯ
  • iga nephroathy
    ¸é¿ª ±Û·ÎºÒ¸° A ½Åº´Áõ
  • secretory IgA
    ºÐºñÇü ¸é¿ª ±Û·ÎºÎ¸° A
    Ç÷û, Ÿ¾×, ´«¹°, È£Èí±â, ¼ÒÈ­°ü µîÀÇ ºÐºñ¾× Áß ÇÔÀ¯µÇ¾î ÀÖ´Ù.
  • acquired perforating dermatosis
    ÈÄõ¼º õ°ø¼º ÇǺκ´
  • acquired reactive perforating dermatosis
    ÈÄõ¼º ¹ÝÀÀ¼º õ°ø¼º ÇǺκ´
  • acute febrile neutrophilic dermatosis
    ±Þ¼º ¹ß¿­¼º È£Áß±¸¼º ÇǺο°
  • angioneurotic dermatosis
    Ç÷°ü ½Å°æ¼º ÇǺκ´
  • benign papular acantholytic dermatosis
    ¾ç¼º ±¸Áø¼º ±Ø¼¼Æ÷ ÇØ¸® ÇǺκ´
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • dermatosis Kaposi
    Ä«Æ÷½Ã ÇǺκ´
  • juvenile plantar dermatosis
    ¿¬¼Ò¼º ¹ß¹Ù´Ú ÇǺκ´
  • parasitic dermatosis
    ±â»ýÃæ ÇǺÎÁõ
  • peridigital dermatosis
    ¼Õ°¡¶ô ÁÖÀ§ ÇǺκ´
  • transient acantholytic dermatosis
    Àϰú¼º ±Ø¼¼Æ÷ ÇØ¸® ÇǺκ´
  • coefficient of linear thermal expansion
    ¿­ ÆØÃ¢ °è¼ö
    ¹°Ã¼ÀÇ ¿Âµµ¸¦ 1µµ »ó½Â½ÃÅ´¿¡ µû¸¥ ±æÀÌÀÇ Áõ°¡À².
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
linear IgA bullous disease in children A rare self-limiting bullous disease, chiefly of the trunk, perioral, and pelvic areas, with onset in the first decade, successively less severe recurrences, and total remission at adolescence; linear epidermal basement membrane zone deposit of IgA is found in involved and in normal skin.
Synonym: linear IgA bullous disease in children.
(05 Mar 2000)
glomerulonephritis, IgA Chronic form of glomerulonephritis characterised by recurring haematuria with only slight proteinuria and by deposits of IgA immunoglobulin in the mesangial areas of the renal glomeruli. It usually occurs in young males.
(12 Dec 1998)
secretory component of IgA <immunology, protein> A polypeptide chain of about 60 kD that aids secretion of the IgA, a portion of the IgA receptor on the plasmalemma of the inner side of the epithelial cells lining the gut, which is proteolysed when the IgA receptor complex has travelled through the cell after receptor mediated endocytosis at the inner face, to the outer (luminal) face.
(18 Nov 1997)
IgA <immunology> Major class of immunoglobulin of external secretions in mammals, also found in serum and body fluids such as tears and saliva and in the respiratory, reproductive, urinary and gastrointestinal tracts.
Immunoglobulin A protects the bodys mucosal surfaces from infection and in secretions, it is found as a dimer (400 kD) joined by a short J chain and linked to a secretory portion or transport piece. In serum found as a monomer (170 kD).
Immunoglobulin A is the main mechanism for providing local immunity against infections in the gut or respiratory tract and may act by reducing the binding between an immunoglobulin A coated micro organism and a host epithelial cell. Present in human colostrum but not transferred across the placenta. Have heavy chains.
(30 Mar 1998)
IgA deficiency A dysgammaglobulinaemia characterised by a deficiency of IgA.
(12 Dec 1998)
IgA nephropathy <nephrology, pathology> This is a form of glomerulonephritis that results from the deposition of circulating IgA antibody in the kidney tissues.
Inflammation of the glomerulus (glomerulonephritis) is the result. This condition may present as acute glomerulonephritis, chronic glomerulonephritis or rapidly progressive glomerulonephritis.
Berger's is usually detected in an individual with one or two bouts of bloody urine (usually begins during or soon after a respiratory infection) and no other symptoms of renal disease. Only rarely, will Berger's disease permanently affect kidney function and progress to chronic renal failure. This renal disorder more commonly affects males in the 16-40 age group.
Origin: Gr. Pathos = disease
(27 Sep 1997)
IgA, secretory The principle ig found in exocrine secretions such as milk, respiratory and intestinal mucin, saliva and tears. It is composed of two to four molecules of 7s IgA and one molecule each of j chain and secretory component (sc), also called secretory piece. Molecular weight appr. 400,000.
(12 Dec 1998)
IgA-specific serine endopeptidase <enzyme> Extracellular microbial enzymes whose only substrate is human IgA of the iga1 subclass; cleave the immunoglobulin at a specific internal prolyl-threonyl peptide bond in the heavy chain to yield intact faba and fca fragments; consider also EC 3.4.24.13
Registry number: EC 3.4.21.72
Synonym: immunoglobulin a(1) protease, iga1 protease, immunoglobulin a1 protease, IgA protease
(26 Jun 1999)
programming, linear A technique of operations research for solving certain kinds of problems involving many variables where a best value or set of best values is to be found. It is most likely to be feasible when the quantity to be optimised, sometimes called the objective function, can be stated as a mathematical expression in terms of the various activities within the system, and when this expression is simply proportional to the measure of the activities, i.e., is linear, and when all the restrictions are also linear. It is different from computer programming, although problems using linear programming techniques may be programmed on a computer.
(12 Dec 1998)
non-linear Not linear.
(05 Dec 1998)
superficial linear keratitis Spontaneous, painful keratitis with epithelial erosion and folds in Bowman's membrane.
(05 Mar 2000)
linear Pertaining to or resembling a line.
Origin: L. Linearis
(18 Nov 1997)
linear absorption coefficient That fraction of ionizing radiation absorbed in a unit thickness of a substance or tissue.
See: absorption coefficient.
(05 Mar 2000)
linear acceleration The rate of change of velocity without a change in direction; e.g., when the speed of an aircraft increases while flying a straight pathway.
(05 Mar 2000)
linear accelerator <apparatus> A sophisticated external beam radiotherapy machine which has the capabilities of focussing irradiation (although not very finely).
Acronym: LinAC
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adulthood
    ¼ºÀÎ(¾î¸¥)ÀÓ;¼ºÀαâ
  • dermatosis
    ÇǺκ´
  • linear
    ÁÙÀÇ
  • linear
    Á÷¼±ÀÇ(À¸·Î ÀÌ·ç¾îÁø);¼±ÀÇ
  • linear accelerator
    ¼±Çü°¡¼Ó±â
  • linear measure
    ôµµ
  • linear motor
    ¼±Çü¸ðÅÍ
  • linear programming
    ¼±Çü°èȹ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á